Study sheds light on H1N1 origins

The new H1N1 virus is only distantly related to its nearest relatives, suggesting that its genes may have been circulating undetected in pig populations for some time, according to new research published online by the journal Science. Scientists also confirm the novel status of the virus, noting that it contains a combination of gene segments that has never been reported before.

"This study reinforces the fact that swine are an important reservoir of influenza viruses with the potential to cause significant respiratory outbreaks or even a possible pandemic in humans, and the results of the study show the global need for more systemic surveillance of influenza viruses in pigs," commented Dr Nancy Cox, one of the authors of the paper and Director of the Influenza Division at the Centers for Disease Control and Prevention (CDC) in the US.

The study was partly supported by the EU through the EMPERIE (European management platform for emerging and re-emerging infectious disease entities) project, which is funded under the Seventh Framework Programme (FP7).

The researchers arrived at their conclusions by sequencing the genomes of over 70 samples of the H1N1 virus, most of which were taken from patients in Mexico and the US.

"From our analysis, we have confirmed that the novel H1N1 virus likely originated from pigs," said Dr Cox, adding that the new virus is very different from human H1N1 viruses, which indicates that "seasonal influenza H1 vaccines may not protect people from infection with this novel virus."

With the help of the samples, the researchers were able to piece together the history of the virus. Six of the eight gene segments studied came from a known strain of swine flu that has been circulating in North America and Asia since 1998. The remaining two segments come from Eurasian swine virus strains that have never been detected outside Eurasia until now. This combination of gene segments has never been seen before.

The samples also turned out to be extremely similar to one another, indicating that the virus crossed into humans just once. Alternatively, very similar viruses may have crossed into humans a number of times.

"While our analysis shows that all gene segments are derived from swine influenza viruses, at this time we do not know if the virus entered the human population directly from swine or via an intermediate host, nor do we know for certain the exact host that the viruses might previously have circulated in to obtain its current properties," Dr Cox pointed out.

She added that veterinary researchers around the world are now delving into their freezers to see if they have samples from pigs or other animals that could shed new light on the emergence of the new virus.

According to Dr Cox, the fact that the viruses are similar "makes our job of coming up with a reference candidate vaccine virus much, much easier."

According to the latest figures from the World Health Organization (WHO), a total of 12,954 cases (including 92 deaths) of H1N1 influenza have been officially diagnosed across 46 countries worldwide. Most of these cases are in the US and Mexico, which have so far reported 6,764 and 4,174 cases respectively.

For further information, please visit:

Copyright ©European Communities, 2009
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...